Abstract
This discussion emphasizes specification of subgroup analyses in the protocol and adjustment of the resulting p-values. The perspective is that of a statistician in the pharmaceutical industry. These comments are derived primarily from discussions with people from various companies, as well as the author's personal experience. These comments do not necessarily represent the philosophy of any past or present supervisors and/or colleagues.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
